HIV microbicide by 2010?

An effective product possible by the end of the decade, but $750m needed, researchers say

Written byRobert Walgate
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

BANGKOK--Researchers need $750 million in additional funding to develop an effective vaginal microbicide that will reduce women's high risk of infection from unprotected sex, experts said at the International AIDS Conference, which closes here today.

In some parts of South Africa, half of all women aged 15 to 24 are now infected with HIV, and “monogamous marriage” was identified at the conference's closing ceremony as a major risk factor for young women, because of men's unfaithfulness.

But a 60% effective microbicide used in 20% of coital acts could save 2.5 million people in 3 years, said Zeda Rosenberg, CEO of the International Partnership for Microbicides (IPM), a 2-year-old public-private partnership created to accelerate research and development (R&D) to create a practical product.

“Microbicides need investment of about $1 billion,” Mark Mitchnick, director of R&D at IPM, told The Scientist. “About $250 m is [already] committed”, including funds to other organizations, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies